Deubiquitinating enzymes as promising drug targets for infectious diseases

Curr Pharm Des. 2013;19(18):3234-47. doi: 10.2174/1381612811319180008.

Abstract

Deubiquitinating enzymes (DUBs) remove ubiquitin and ubiquitin-like modifications from proteins and they have been known to contribute to processes relevant in microbial infection, such as immune responses pathways. Numerous viral and bacterial DUBs have been identified, and activities of several host DUBs are known to be modulated during the infection process, either by a pathogen or by a host. Recently there have been attempts to take advantage of this feature and design therapeutic inhibitors of DUBs that can be used to limit the spread of infection. This review is focused on exploring the potential of DUBs in the treatment of infectious diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology*
  • Bacterial Proteins / metabolism
  • Communicable Diseases / drug therapy*
  • Communicable Diseases / microbiology
  • Drug Design
  • Endopeptidases / metabolism*
  • Humans
  • Molecular Targeted Therapy
  • Protein Processing, Post-Translational
  • Ubiquitin / metabolism
  • Ubiquitination
  • Viral Proteins / metabolism

Substances

  • Anti-Infective Agents
  • Bacterial Proteins
  • Ubiquitin
  • Viral Proteins
  • Endopeptidases